Advertisement

Journal of Nephrology

, Volume 31, Issue 2, pp 257–262 | Cite as

Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome

  • Matija CrnogoracEmail author
  • Ivica Horvatic
  • Patricia Kacinari
  • Danica Galesic Ljubanovic
  • Kresimir Galesic
Original Article

Abstract

Aim

To determinate the prognostic significance of low serum C3 at the time of diagnosis of ANCA-associated vasculitis (AAV).

Methods

Our cohort included 75 consecutive patients with AAV diagnosed from January 2005 to December 2015. C3 levels were measured at the time of diagnosis. Patients were divided into two groups, those with low serum C3 levels (< 0.9 g/l) and those with normal serum C3 levels (0.9–1.8 g/l). We analysed association between serum C3 levels and both combined and singularly patient and renal survival (ESRD). Small number of relapsed patients did not allow for the statistical analysis to be performed as to weather the low serum C3 is associated with relapse rate in AAV patients.

Results

Low serum C3 levels were significantly associated with worse combined end-point patient and renal survival (HR 3.079; 95% CI 1.231–7.701; p = 0.016), and on multivariate adjusted analysis association remained significant (HR 2.831; 95% CI 1.093–7.338; p = 0.032). For both end-points individually low serum C3 levels were significantly associated with poorer patient survival (HR 6.378; 95% CI 2.252–18.065; p < 0.001; on multivariate adjusted analysis HR 4.315 95% CI 1.350–13.799; p = 0.014) and renal survival (HR 3.207; 95% CI 1.040–9.830; p = 0.043; on multivariate adjusted analysis HR 3.679; 95% CI 1.144–11.827; p = 0.029). In our study there was no significant association between serological and patohistological phenotypes and serum C3 levels.

Conclusion

Lower serum C3 levels at the diagnosis is associated with poorer patient and renal outcomes in AAV patients.

Keywords

ANCA Vasculitis C3 factor Complement Anti myeloperoxidase autoantibodies Anti proteinase-3 autoantibodies Prognostic factors 

Notes

Compliance with ethical standards

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Since this is a retrospective study formal consent is not required.

Conflict of interest

All of the authors: Matija Crnogorac, Ivica Horvatic, Patricia Kacinari, Danica Galesic Ljubanovic and Kresimir Galesic declare no conflict of interest.

References

  1. 1.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–1CrossRefPubMedGoogle Scholar
  2. 2.
    Binda V, Moroni G, Messa P (2017) ANCA-associated vasculitis with renal involvement. J Nephrol. https://doi.org/10.1007/s40620-017-0412-z
  3. 3.
    Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW et al (2008) Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 67(7):1004–1010CrossRefPubMedGoogle Scholar
  4. 4.
    Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noël LH, Waldherr R et al (2002) Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 62(5):1732–1742CrossRefPubMedGoogle Scholar
  5. 5.
    Neumann I, Kain R, Regele H, Soleiman A, Kandutsch S, Meisl FT (2005) Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transpl 20:96–104CrossRefGoogle Scholar
  6. 6.
    Hilhorst M, Wilde B, Van Breda VP, Van Paassen P, Tervaert JWC (2013) Estimating renal survival using the ANCA-associated GN classification. J Am Soc Nephrol 24:1371–1375CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Diaz-Crespo F, Villacorta J, Acevedo M, Cavero T, Guerrero C, Díaz EG et al (2016) The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study. Hum Pathol 52:119–127CrossRefPubMedGoogle Scholar
  8. 8.
    Córdova-Sánchez BM, Mejía-Vilet JM, Morales-Buenrostro LE, Loyola-Rodríguez G, Uribe-Uribe NO, Correa-Rotter R (2016) Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin Rheumatol 35:1805–1816Google Scholar
  9. 9.
    Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70(3):488–494CrossRefPubMedGoogle Scholar
  10. 10.
    De Joode AAE, Sanders JAF, Stegeman CA (2013) Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 8(10):1709–1717CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hilhorst M, van Paassen P, van Rie H, Bijnens N, Heerings-Rewinkel P, van Breda Vriesman P et al (2017) Complement in ANCA-associated glomerulonephritis. Nephrol Dial Transpl 32(8):1302–1313CrossRefGoogle Scholar
  12. 12.
    Gou SJ, Yuan J, Chen M, Yu F, Zhao MH (2013) Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 83(1):129–137CrossRefPubMedGoogle Scholar
  13. 13.
    Augusto JF, Langs V, Demiselle J, Lavigne C, Brilland B, Duveau A, Poli C, Chevailler A, Crou A, Tollis F, Sayegh J, Subra JF. Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis. PloS One 11(7): e0158871Google Scholar
  14. 14.
    Manenti L, Vaglio A, Gnappi E, Maggiore U, Allegri L, Allinovi M et al (2015) Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis. Clin J Am Soc Nephrol 10(12):2143–2151CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K et al (2010) Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21(10):1628–1636CrossRefPubMedGoogle Scholar
  16. 16.
    Huugen D, van Esch A, Xiao H, Peutz-Kootstra CJ, Buurman WA, Tervaert JW et al (2007) Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 71(7):646–654CrossRefPubMedGoogle Scholar
  17. 17.
    Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC (2007) Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170(1):52–64CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Gou SJ, Yuan J, Wang C, Zhao MH, Chen M (2013) Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin J Am Soc Nephrol 8(11):1884–1891CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Molad Y, Tovar A, Ofer-Shiber S (2014) Association of low serum complement C3 with reduced patient and renal survival in antimyeloperoxidase-associated small-vessel vasculitis. Nephron Clin Pract 126(1):67–74CrossRefPubMedGoogle Scholar
  20. 20.
    Magen E, Mishal J, Paskin J, Glick Z, Yosefy C, Kidon M, Schlesinger M (2008) Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. J Clin Hypertens 10(9):677–683CrossRefGoogle Scholar
  21. 21.
    Barbour T, Johnson S, Cohney S, Hughes P (2012) Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transpl 27(7):2673–2685CrossRefGoogle Scholar
  22. 22.
    Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ (2012) C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 82(4):465–473CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Alexander MP, Fervenza FC, De Vriese AS, Smith RJH, Nasr SH, Cornell LD, Herrera Hernandez LP, Zhang Y, Sethi S (2016) C3 glomerulonephritis and autoimmune disease: more than a fortuitous association? J Nephrol 29(2):203–209CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Nephrology 2017

Authors and Affiliations

  1. 1.Department of Nephrology and DialysisDubrava University HospitalZagrebCroatia
  2. 2.Department of PathologyDubrava University HospitalZagrebCroatia

Personalised recommendations